A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2019-02-06
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multicenter study to evaluate the safety and efficacy of BG
induction therapy in participants with previously untreated CLL. The anticipated time on
study treatment is 24 weeks.